Search

Your search keyword '"Ebrahimi, Hedyeh"' showing total 282 results

Search Constraints

Start Over You searched for: Author "Ebrahimi, Hedyeh" Remove constraint Author: "Ebrahimi, Hedyeh"
282 results on '"Ebrahimi, Hedyeh"'

Search Results

1. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

2. Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations

3. Reply by Authors

4. Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors

5. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research

7. Multicenter analysis of high-dose chemotherapy (HDCT) regimens for the treatment of patients (pts) with recurrent germ cell tumors (GCTs).

8. Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).

9. Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy

10. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

11. The burden of ischemic heart disease and its attributable risk factors in North Africa and Middle East, 1990‐2019: Results from the GBD study 2019

12. Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors

13. Reply by Authors

14. Supplementary table 1 from Unique Spectrum of Activating BRAF Alterations in Prostate Cancer

15. Supplementary Data 1 from Unique Spectrum of Activating BRAF Alterations in Prostate Cancer

16. Supplementary Figure 1 from Unique Spectrum of Activating BRAF Alterations in Prostate Cancer

17. Data from Unique Spectrum of Activating BRAF Alterations in Prostate Cancer

18. Supplementary table 2 from Unique Spectrum of Activating BRAF Alterations in Prostate Cancer

20. CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC)

21. The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

22. Risk of incident cardiovascular diseases at national and subnational levels in Iran from 2000 to 2016 and projection through 2030: Insights from Iran STEPS surveys

23. Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations

24. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy

25. Unique Spectrum of Activating BRAF Alterations in Prostate Cancer

26. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016

27. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016

28. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

29. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.

30. Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).

31. Adherence to American Society of Clinical Oncology (ASCO) language of respect (LoR) guidelines in ASCO Annual Meeting prostate cancer (PCa) abstracts.

32. Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract.

33. Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).

34. Adherence to ASCO Language of Respect (LoR) guidelines in urothelial carcinoma (UC) abstracts at the 2023 ASCO Annual Meeting.

36. Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial.

37. Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.

38. From guidelines to accountability: Examining adherence to ASCO Language of Respect in renal cell carcinoma (RCC) abstracts.

39. Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).

40. Association between thymectomy and incidence of renal cell carcinoma (RCC).

43. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015

44. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

45. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

46. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

47. eLife's new model and its impact on science communication

48. Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma.

49. Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).

Catalog

Books, media, physical & digital resources